化疗在晚期非小细胞肺癌治疗中的地位和价值

被引：5

作者：

陈申 ^{[1
]}

马锐 ^{[2
]}

机构：

[1] 大连医科大学研究生院

[2] 辽宁省肿瘤医院大连医科大学临床肿瘤学院

来源：

中国肿瘤 | 2015年 / 24卷 / 09期

关键词：

非小细胞肺癌; 靶向治疗; 化疗;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

化疗于晚期非小细胞肺癌治疗依然具有举足轻重的作用。以IPASS研究为代表的一系列靶向治疗与化疗头对头对比研究,也证实了化疗依旧是EGFR野生型及突变未明患者一线治疗的首要选择。DELTA研究及CTONG0806研究结果则表明二线治疗中化疗比靶向治疗疗效更优。而LUX-LUNG3/6研究生存数据则表明21外显子突变患者可能更适合于一线化疗。总而言之,化疗是晚期非小细胞肺癌治疗全程管理中不可或缺的。

引用

页码：737 / 741

页数：5

共 13 条

[1]

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials [J].

Yang, James Chih-Hsin ;

Wu, Yi-Long ;

Schuler, Martin ;

Sebastian, Martin ;

Popat, Sanjay ;

Yamamoto, Nobuyuki ;

Zhou, Caicun ;

Hu, Cheng-Ping ;

O'Byrne, Kenneth ;

Feng, Jifeng ;

Lu, Shun ;

Huang, Yunchao ;

Geater, Sarayut L. ;

Lee, Kye Young ;

Tsai, Chun-Ming ;

Gorbunova, Vera ;

Hirsh, Vera ;

Bennouna, Jaafar ;

Orlov, Sergey ;

Mok, Tony ;

Boyer, Michael ;

Su, Wu-Chou ;

Lee, Ki Hyeong ;

Kato, Terufumi ;

Massey, Dan ;

Shahidi, Mehdi ;

Zazulina, Victoria ;

Sequist, Lecia V. .

LANCET ONCOLOGY, 2015, 16 (02) :141-151

[2]

Cancer Statistics, 2015 [J].

Siegel, Rebecca L. ;

Miller, Kimberly D. ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (01) :5-29

[3]

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial [J].

Wu, Yi-Long ;

Zhou, Caicun ;

Hu, Cheng-Ping ;

Feng, Jifeng ;

Lu, Shun ;

Huang, Yunchao ;

Li, Wei ;

Hou, Mei ;

Shi, Jian Hua ;

Lee, Kye Young ;

Xu, Chong-Rui ;

Massey, Dan ;

Kim, Miyoung ;

Shi, Yang ;

Geater, Sarayut L. .

LANCET ONCOLOGY, 2014, 15 (02) :213-222

[4]

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations [J].

Sequist, Lecia V. ;

Yang, James Chih-Hsin ;

Yamamoto, Nobuyuki ;

O'Byrne, Kenneth ;

Hirsh, Vera ;

Mok, Tony ;

Geater, Sarayut Lucien ;

Orlov, Sergey ;

Tsai, Chun-Ming ;

Boyer, Michael ;

Su, Wu-Chou ;

Bennouna, Jaafar ;

Kato, Terufumi ;

Gorbunova, Vera ;

Lee, Ki Hyeong ;

Shah, Riyaz ;

Massey, Dan ;

Zazulina, Victoria ;

Shahidi, Mehdi ;

Schuler, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3327-+

[5]

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer.[J].Luis G. Paz-Ares;Filippo de Marinis;Mircea Dediu;Michael Thomas;Jean-Louis Pujol;Paolo Bidoli;Olivier Molinier;Tarini Prasad Sahoo;Eckart Laack;Martin Reck;Jesús Corral;Symantha Melemed;William John;Nadia Chouaki;Annamaria H. Zimmermann;Carla Visseren-Grul;Cesare Gride

[6]

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.[J].Marina Chiara Garassino;Olga Martelli;Massimo Broggini;Gabriella Farina;Silvio Veronese;Eliana Rulli;Filippo Bianchi;Anna Bettini;Flavia Longo;Luca Moscetti;Maurizio Tomirotti;Mirko Marabese;Monica Ganzinelli;Calogero Lauricella;Roberto Labianca;Irene Floriani;Giuseppe Giaccone;Valter Torri;Alberto Scanni;Silvia Marsoni.La

[7]

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial.[J].Mark A. Socinski;Igor Bondarenko;Nina A. Karaseva;Anatoly M. Makhson;Igor Vynnychenko;Isamu Okamoto;Jeremy K. Hon;Vera Hirsh;Paul Bhar;Hui Zhang;Jose L. Iglesias;Markus F. Renschler.Journal of Clinical Oncology.2012, 17

[8]

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study [J].

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Miliauskas, Skaidrius ;

Grigorescu, Alexandru Calin ;

Hillenbach, Carina ;

Johannsdottir, Hrefna Kristin ;

Klughammer, Barbara ;

Esteban Gonzalez, Emilio .

LANCET ONCOLOGY, 2012, 13 (03) :300-308

[9]

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[10]

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study [J].

Zhou, Caicun ;

Wu, Yi-Long ;

Chen, Gongyan ;

Feng, Jifeng ;

Liu, Xiao-Qing ;

Wang, Changli ;

Zhang, Shucai ;

Wang, Jie ;

Zhou, Songwen ;

Ren, Shengxiang ;

Lu, Shun ;

Zhang, Li ;

Hu, Chengping ;

Hu, Chunhong ;

Luo, Yi ;

Chen, Lei ;

Ye, Ming ;

Huang, Jianan ;

Zhi, Xiuyi ;

Zhang, Yiping ;

Xiu, Qingyu ;

Ma, Jun ;

Zhang, Li ;

You, Changxuan .

LANCET ONCOLOGY, 2011, 12 (08) :735-742

← 1 2 →